Amount To Be Received Upon Completion Of Transfer

No definition available.

Name:	rgen_AmountToBeReceivedUponCompletionOfTransfer
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Non Contingent Consideration Being Recognized As Revenue Over Estimated Period Of Performance

+ References

No definition available.

+ Details

Name:	rgen_NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformance
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Nonrefundable Upfront Cash Payment Under Collaborations Agreement

+ References

No definition available.

+ Details

Name:	rgen_NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage Of Future Milestone Payments

+ References

No definition available.

+ Details

Name:	rgen_PercentageOfFutureMilestonePayments
Namespace Prefix:	rgen_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential Additional Milestone Payments Associated With Potential Regulatory Approvals

+ References

No definition available.

+ Details

Name:	rgen_PotentialAdditionalMilestonePaymentsAssociatedWithPotentialRegulatoryApprovals
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Provision For Wholesale Refunds

+ References

No definition available.

+ Details

Name:	rgen_ProvisionForWholesaleRefunds
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized that was previously reported as deferred or unearned revenue.

+ References

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgen_ClinicalResearchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgen_FirstCommercialSaleMilestoneEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MajorCustomersAxis=rgen_BiomarinPharmaceuticalIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=rgen_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgen_TechnologyTransferPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue Recognition - Additional Information (Detail) - USD ($)			3 Months Ended	6 Months Ended
	Sep. 03, 2014	Jan. 30, 2014	Mar. 31, 2014	Jun. 30, 2016
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Non-refundable up-front payment				$ 2,000,000
Payment to be received upon signing of agreement				125,675
Revenue recognized				2,115,000
Revenue recognized under revenue recognition, up front payment			$ 2,000,000
Clinical Development
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone Payment				60,000,000
Potential milestone payments to be received				60,000,000
Initial Commercial Sales
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Potential milestone payments to be received				100,000,000
BioMarin Pharmaceutical, Inc. \| Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront payment received under purchase agreement		$ 2,000,000
Potential milestone payments to be received				160,000,000
Provision for refund				$ 0
BioMarin Pharmaceutical, Inc. \| Clinical Development \| Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage relate to clinical development from Milestone payment				37.00%
BioMarin Pharmaceutical, Inc. \| Initial Commercial Sales \| Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage relate to clinical development from Milestone payment				63.00%
BioMarin Pharmaceutical, Inc. \| Technology Transfer Payments \| Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone Payment	$ 125,675